BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Docetaxel: trial readouts and FDA decisions

17 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 15 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Sichuan Baili Pharmaceutical Co., Ltd., Akeso, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Merck Sharp & Dohme LLC, Shanghai JMT-Bio Inc., Amgen, Jiangsu HengRui Medicine Co., Ltd., Nanjing Leads Biolabs Co.,Ltd. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P3Merck Sharp & Dohme LLC MRKNCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer Endometrial Neoplasmsactive not recruiting990
2026-11-30 est.P1/P2Amgen AMGNNCT05094336 A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Advanced MTAP-null Solid Tumorsactive not recruiting329
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05054439 A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCHead and Neck Squamous Cell Carcinomaactive not recruiting45
2026-12 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06382129 A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)Non-small Cell Lung Canceractive not recruiting698
2026-12 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT06568094 A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerProstate Cancerrecruiting100
2026-12 est.P1/P2AkesoNCT06943820 AK129 Combination Therapy for Advanced Solid TumorsNon-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal recruiting230
2026-12-16 est.P3Shanghai JMT-Bio Inc.NCT06747338 A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerEarly or Locally Advanced HER2-positive Breast Canceractive not recruiting520
2026-12-24 est.P2Nanjing Leads Biolabs Co.,LtdNCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]Advanced Solid Tumourrecruiting250
2026-12-25 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06525350 A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpressionot yet recruiting256
2026-12-30 est.P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05631262 SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsSelected Subjects With Advanced Solid Tumorsactive not recruiting321
2026-12-30 est.P3Beijing Konruns Pharmaceutical Co., Ltd.NCT06194734 A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerEsophageal Squamous Cell Carcinomarecruiting490
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2AskGene Pharma, Inc.NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.Advanced Solid Tumorsrecruiting594
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01 est.P1/P2iOncturaNCT06879717 A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsNon-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLCactive not recruiting45
2027-02 est.P1/P2Krystal Biotech, Inc. KRYSNCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsLung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cancerecruiting250
2027-02 est.P2Genelux Corporation GNLXNCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerAdvanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Mrecruiting142

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Nasopharyngeal Carcinomaactive not recruiting386
2026-10-19P3Merck Sharp & Dohme LLC MRKNCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Gastroesophageal Canceractive not recruiting473
2026-10 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06300177 D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Non Small Cell Lung Cancerrecruiting522
2026-09-03P3Novartis Pharmaceuticals NVSNCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerNon-Small Cell Lung Cancerterminated95
2026-09 est.P1/P2Qilu Pharmaceutical Co., Ltd.NCT06949761 A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced SoSolid Tumornot yet recruiting240
2026-07-15 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07116824 HB1801 Combined Treatment of HER2-positive Breast CancerHER2-positive Breast Cancernot yet recruiting80
2026-07-03 est.P3Boehringer IngelheimNCT06370871 Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS)withdrawn
2026-07-01 est.P2/P3Shanghai JMT-Bio Inc.NCT06319313 Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerSquamous Cell Non-small Cell Lung Cancernot yet recruiting534
2026-07 est.P3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06738251 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial CarcinomaAdvanced Urothelial Carcinomarecruiting402
2026-07 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT05943795 A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaNon-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lungactive not recruiting589
2026-07 est.P2AkesoNCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCNSCLCactive not recruiting265
2026-06-30 est.P1/P2AkesoNCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerAdvanced Non-small-cell Lung Canceractive not recruiting233
2026-06-17P3Hansoh BioMedical R&D CompanyNCT06935409 Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureOsteosarcomacompleted122
2026-06-01 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06296706 A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric CancerGastric Cancerrecruiting630
2026-05-31P3AstraZeneca AZNNCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdGastric Cancer; Gastroesophageal Junction Canceractive not recruiting594

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.